Fewer HIV diagnoses due to improved HIV prevention and treatment tools
- Submitting institution
-
King's College London
- Unit of assessment
- 1 - Clinical Medicine
- Summary impact type
- Health
- Request cross-referral to
- -
- Is this case study continued from a case study submitted in 2014?
- No
- Underpinning research subjects
-
- Clinical Sciences
- Medical Microbiology
- Public Health And Health Services
3. References to the research
5. Sources to corroborate the impact
Additional contextual information
Grant funding
| Grant number |
Value of grant |
| RIA2016MC-1616 |
£30,000,000 |
| RIA2020EF-3008 |
£10,000,000 |
| RIA2016V-1644 |
£15,000,000 |
- Countries
-
- South Africa
- Uganda
- Zimbabwe
- South Africa
- Uganda
- United Kingdom
- Uganda
- Tanzania
- Mozambique
- South Africa
- Formal partners
-
- Imperial College of Science, Technology and Medicine
- University of Liverpool
- Karolinska Institutet
- London School of Hygiene and Tropical Medicine
- University of Cape Town
- Wits Health Consortium (Pty) Ltd.
- Desmond Tutu HIV Foundation
- University of Zimbabwe
- Imperial College of Science Technology and Medicine
- Karolinska Institutet
- Uganda Virus Research Institute
- London School of Hygiene and Tropical Medicine
- Perinatal HIV Research Unit
- Imperial College of Science Technology and Medicine
- MRC/UVRI Uganda Research Institute on AIDS
- Karolinska Institutet
- Ludwig-Maximilians-Universitaet
- Muhimbili University of Health & Allied Sciences
- National Institute for Medical Research - Tanzania
- Instituto Nacional de Saude (INS) – Mozambique
- Medical Research Council (MRC) - South Africa
- Centre Hospitalier Universitaire Vaudois
- University of KwaZulu-Natal
- University College London
- US Military HIV Research Program
- EuroVacc Foundation
- International AIDS Vaccine Initiative
- Funding programmes
-
- CHAPS - Combined HIV African Prevention Study: On demand Truvada and F/TAF Pre-exposure and Postexposure prophylaxis to protect adolescents from HIV
- COVAB - Investigating COVID-19 infectiousness and antibody evolution in COVID-19 PATIENTS in SSA and Europe
- PrEPVaCC - A combination efficacy study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEP)
- Global research identifiers
-
- grid.453375.3
- grid.453375.3
- grid.453375.3
- Name of funders
-
- Researcher ORCIDs
-
- 0000-0002-0583-8019
- 0000-0003-3701-752X
- 0000-0002-4936-1718
- 0000-0002-2769-0967
- 0000-0002-1385-8343
- 0000-0003-3547-7936
- 0000-0002-0583-5272
- 0000-0002-9293-901X
- 0000-0002-0184-5705
- 0000-0002-1949-3138
- 0000-0002-0755-4386
- 0000-0002-6616-429X
- 0000-0003-3566-1688
- 0000-0002-4019-7456
- 0000-0001-9706-2977
- 0000-0002-0583-8019
- 0000-0003-3701-752X
- 0000-0002-1385-8343
- 0000-0002-0184-5705
- 0000-0001-9706-2977
- 0000-0002-0583-5272
- 0000-0002-0583-8019
- 0000-0002-4131-2962
- 0000-0002-6880-6655
- 0000-0001-9706-2977
- 0000-0001-7519-0628
- 0000-0003-3743-1317
- 0000-0002-2533-3982
- 0000-0003-1524-6778
- 0000-0002-7642-1835
- 0000-0002-7829-1325
- 0000-0003-2431-244X
- 0000-0001-8069-1056
- 0000-0003-3949-9649
